Pardoprunox

Summary

Pardoprunox (CHEMBL2103832) is a phase-3 clinical-stage small molecule; indicated across 1 condition including parkinson disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 233.27 Da · C12H15N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103832
Name	Pardoprunox
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918525
Molecular formula	C12H15N3O2
Molecular weight	233.27
InChIKey	YVPUUUDAZYFFQT-UHFFFAOYSA-N

SMILES: CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3

IUPAC name: 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one

Also known as: DU 126891, DU-126891, DU126891, Pardoprunox, SLV 308, SLV-308, SLV308, PARDOPRUNOX, Pardoprunox (hydrochloride)

Parent form; salt/anhydrous children: CHEMBL2105649

Patent coverage: 76 distinct patent families (159 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 122 (77%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	3	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00134251	PHASE3	COMPLETED	Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson’s Disease
NCT00269516	PHASE3	COMPLETED	SLV308 for Treatment of Patients With Early Parkinson’s Disease
NCT00332917	PHASE3	COMPLETED	An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
NCT00335374	PHASE3	COMPLETED	An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
NCT00407095	PHASE3	COMPLETED	An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson’s Disease Experiencing Motor Fluctuations.
NCT00903838	PHASE2	TERMINATED	A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).